775 related articles for article (PubMed ID: 24853387)
1. Chronic cannabinoid receptor 2 activation reverses paclitaxel neuropathy without tolerance or cannabinoid receptor 1-dependent withdrawal.
Deng L; Guindon J; Cornett BL; Makriyannis A; Mackie K; Hohmann AG
Biol Psychiatry; 2015 Mar; 77(5):475-87. PubMed ID: 24853387
[TBL] [Abstract][Full Text] [Related]
2. CB1 Knockout Mice Unveil Sustained CB2-Mediated Antiallodynic Effects of the Mixed CB1/CB2 Agonist CP55,940 in a Mouse Model of Paclitaxel-Induced Neuropathic Pain.
Deng L; Cornett BL; Mackie K; Hohmann AG
Mol Pharmacol; 2015 Jul; 88(1):64-74. PubMed ID: 25904556
[TBL] [Abstract][Full Text] [Related]
3. Cannabinoid CB2 Agonist AM1710 Differentially Suppresses Distinct Pathological Pain States and Attenuates Morphine Tolerance and Withdrawal.
Li AL; Lin X; Dhopeshwarkar AS; Thomaz AC; Carey LM; Liu Y; Nikas SP; Makriyannis A; Mackie K; Hohmann AG
Mol Pharmacol; 2019 Feb; 95(2):155-168. PubMed ID: 30504240
[TBL] [Abstract][Full Text] [Related]
4. Prophylactic cannabinoid administration blocks the development of paclitaxel-induced neuropathic nociception during analgesic treatment and following cessation of drug delivery.
Rahn EJ; Deng L; Thakur GA; Vemuri K; Zvonok AM; Lai YY; Makriyannis A; Hohmann AG
Mol Pain; 2014 Apr; 10():27. PubMed ID: 24742127
[TBL] [Abstract][Full Text] [Related]
5. The maintenance of cisplatin- and paclitaxel-induced mechanical and cold allodynia is suppressed by cannabinoid CB₂ receptor activation and independent of CXCR4 signaling in models of chemotherapy-induced peripheral neuropathy.
Deng L; Guindon J; Vemuri VK; Thakur GA; White FA; Makriyannis A; Hohmann AG
Mol Pain; 2012 Sep; 8():71. PubMed ID: 22998838
[TBL] [Abstract][Full Text] [Related]
6. Cannabinoid CB
Li AL; Carey LM; Mackie K; Hohmann AG
J Pharmacol Exp Ther; 2017 Aug; 362(2):296-305. PubMed ID: 28592614
[TBL] [Abstract][Full Text] [Related]
7. A peripheral CB2 cannabinoid receptor mechanism suppresses chemotherapy-induced peripheral neuropathy: evidence from a CB2 reporter mouse.
Lin X; Xu Z; Carey L; Romero J; Makriyannis A; Hillard CJ; Ruggiero E; Dockum M; Houk G; Mackie K; Albrecht PJ; Rice FL; Hohmann AG
Pain; 2022 May; 163(5):834-851. PubMed ID: 35001054
[TBL] [Abstract][Full Text] [Related]
8. Positive Allosteric Modulation of Cannabinoid Receptor Type 1 Suppresses Pathological Pain Without Producing Tolerance or Dependence.
Slivicki RA; Xu Z; Kulkarni PM; Pertwee RG; Mackie K; Thakur GA; Hohmann AG
Biol Psychiatry; 2018 Nov; 84(10):722-733. PubMed ID: 28823711
[TBL] [Abstract][Full Text] [Related]
9. Antiallodynic effect of β-caryophyllene on paclitaxel-induced peripheral neuropathy in mice.
Segat GC; Manjavachi MN; Matias DO; Passos GF; Freitas CS; Costa R; Calixto JB
Neuropharmacology; 2017 Oct; 125():207-219. PubMed ID: 28729222
[TBL] [Abstract][Full Text] [Related]
10. The cannabinoid CB
Iyer V; Slivicki RA; Thomaz AC; Crystal JD; Mackie K; Hohmann AG
Eur J Pharmacol; 2020 Nov; 886():173544. PubMed ID: 32896549
[TBL] [Abstract][Full Text] [Related]
11. Peripherally administered cannabinoid receptor 2 (CB
Wilkerson JL; Alberti LB; Thakur GA; Makriyannis A; Milligan ED
Brain Res; 2022 Jan; 1774():147721. PubMed ID: 34774500
[TBL] [Abstract][Full Text] [Related]
12. Role of CB1 and CB2 cannabinoid receptors in the development of joint pain induced by monosodium iodoacetate.
La Porta C; Bura SA; Aracil-Fernández A; Manzanares J; Maldonado R
Pain; 2013 Jan; 154(1):160-174. PubMed ID: 23199705
[TBL] [Abstract][Full Text] [Related]
13. Peripheral deficiency and antiallodynic effects of 2-arachidonoyl glycerol in a mouse model of paclitaxel-induced neuropathic pain.
Thomas A; Okine BN; Finn DP; Masocha W
Biomed Pharmacother; 2020 Sep; 129():110456. PubMed ID: 32603895
[TBL] [Abstract][Full Text] [Related]
14. Slowly Signaling G Protein-Biased CB
Lin X; Dhopeshwarkar AS; Huibregtse M; Mackie K; Hohmann AG
Mol Pharmacol; 2018 Feb; 93(2):49-62. PubMed ID: 29192123
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological characterization of AM1710, a putative cannabinoid CB2 agonist from the cannabilactone class: antinociception without central nervous system side-effects.
Rahn EJ; Thakur GA; Wood JA; Zvonok AM; Makriyannis A; Hohmann AG
Pharmacol Biochem Behav; 2011 Jun; 98(4):493-502. PubMed ID: 21382397
[TBL] [Abstract][Full Text] [Related]
16. Peripheral versus central mechanisms of the cannabinoid type 2 receptor agonist AM1710 in a mouse model of neuropathic pain.
Wilkerson JL; Alberti LB; Kerwin AA; Ledent CA; Thakur GA; Makriyannis A; Milligan ED
Brain Behav; 2020 Dec; 10(12):e01850. PubMed ID: 32977358
[TBL] [Abstract][Full Text] [Related]
17. Monoacylglycerol Lipase Inhibitors Reverse Paclitaxel-Induced Nociceptive Behavior and Proinflammatory Markers in a Mouse Model of Chemotherapy-Induced Neuropathy.
Curry ZA; Wilkerson JL; Bagdas D; Kyte SL; Patel N; Donvito G; Mustafa MA; Poklis JL; Niphakis MJ; Hsu KL; Cravatt BF; Gewirtz DA; Damaj MI; Lichtman AH
J Pharmacol Exp Ther; 2018 Jul; 366(1):169-183. PubMed ID: 29540562
[TBL] [Abstract][Full Text] [Related]
18. Effects of Cannabinoid Agonists and Antagonists on Sleep and Breathing in Sprague-Dawley Rats.
Calik MW; Carley DW
Sleep; 2017 Sep; 40(9):. PubMed ID: 28934522
[TBL] [Abstract][Full Text] [Related]
19. Indomethacin plus minocycline coadministration relieves chemotherapy and antiretroviral drug-induced neuropathic pain in a cannabinoid receptors-dependent manner.
Masocha W; Thomas A
J Pharmacol Sci; 2019 Apr; 139(4):325-332. PubMed ID: 30871874
[TBL] [Abstract][Full Text] [Related]
20. Cannabidiol inhibits sucrose self-administration by CB1 and CB2 receptor mechanisms in rodents.
Bi GH; Galaj E; He Y; Xi ZX
Addict Biol; 2020 Jul; 25(4):e12783. PubMed ID: 31215752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
